Industry Record

Amino Asylum: Reported Events, Documented Records, Open Questions

Published: August 26, 2026

By the Curo Research Team

People searching for what happened to Amino Asylum encounter two different kinds of material. One is a repeated account in research-vendor reporting: a federal or FDA warehouse action in June 2025, followed by the original storefront going offline, pending orders remaining unfulfilled, and no customer notice. The other is the public government record. Those records do not currently provide a release, indictment, or charging document that names Amino Asylum.

That distinction controls this article. A widely repeated account can be useful without becoming a court-established fact. The aim here is to state the reporting as reporting, state the public records plainly, and identify what remains unknown. The same method also helps researchers assess any supplier or successor that uses a familiar name.

TL;DR

Industry reporting widely describes a federal or FDA action at an Amino Asylum warehouse in June 2025.
Those reports say the original site went offline immediately and did not return, leaving pending orders unfulfilled without a customer notice.
No public FDA or DOJ release, indictment, or charging document naming the company has been identified, so the warehouse action should not be presented as an adjudicated fact.
The documented Paradigm Peptides case involved products sold as SARMs that federal investigators found contained testosterone, but that is a separate company and record.
Any site now using the old name should be evaluated as a new supplier, beginning with identity, lot records, and independently issued batch documentation.

The timeline as reported

Industry reporting places the central event in June 2025. Across those accounts, the sequence is consistent: federal or FDA personnel reportedly acted at the vendor's warehouse, the original online store stopped operating immediately afterward, open orders were not fulfilled, and customers received no company notice explaining the interruption.

The phrase Amino Asylum raid has become shorthand for that sequence. Shorthand can blur the quality of the evidence, however. The warehouse action is widely reported by industry publications and trackers, but it is not supported in the materials reviewed for this article by a public FDA announcement, DOJ release, indictment, complaint, or charging document naming the business.

The narrow chronology is therefore:

Before June 2025, the company operated an online research-product storefront.
In June 2025, industry sources reported federal or FDA activity at its warehouse.
Those sources reported that the original storefront went offline immediately after the reported action.
Industry accounts described pending orders as unfulfilled and said no customer notice was issued.
Reporting describes the original operation as never returning. Later sites using similar branding are a separate identity question.

This chronology does not establish who participated in the reported action, what authority supported it, what materials may have been collected, or whether any legal proceeding followed. Those details remain outside the identified public record.

For researchers comparing active sources after the shutdown, the starting point should be current documentation, not familiarity with a former brand. Curo's research catalog and batch listings provide one example of how products and their supporting records can be reviewed together, with publicly readable batch certificates available separately. A broader 2026 guide to research peptide companies offers additional context for evaluating supplier evidence without relying on a single closure story.

What is documented versus what is only reported

This is the central distinction. Three evidence categories apply: primary public records, attributed industry reporting, and unresolved questions. Combining them into one narrative would make the account sound more certain than the available material allows.

Documented in a separate federal record

The DOJ case page for United States v. Matthew Kawa concerns Paradigm Peptides, also identified by the government as Paradigm R.E. LLC. The page says the business sold products including peptides, hCG, and SARMs. It further states that federal investigators determined many products advertised, labeled, and sold as containing SARMs instead contained testosterone, a controlled substance.

The DOJ page also records guilty pleas by Matthew Kawa and Jennifer Stechkober on December 10, 2025, followed by sentencing on July 30, 2026. These are primary-record facts about the Paradigm Peptides case. They are not findings about Amino Asylum.

That separation matters because some later industry summaries have blended the two stories. The public page names Paradigm Peptides and its operators. It does not name Amino Asylum, describe the reported June 2025 warehouse action, or establish a legal connection between the businesses. The Paradigm matter is relevant only as documented context from the same broad period.

Widely reported, but not established by an identified public filing

Industry reporting consistently describes a June 2025 federal or FDA warehouse action involving Amino Asylum. It also consistently describes the immediate loss of the storefront, unfulfilled pending orders, and an absence of customer communication. One industry account explicitly notes that it could not locate a public DOJ release, FDA release, indictment, unsealed complaint, or seizure order naming the vendor.

Any account of the Amino Asylum raid should keep that attribution attached. The accurate formulation is that the action was widely reported, not that a court determined it occurred or that the government publicly described it. Likewise, the reported order and communication problems belong to industry accounts, not to a government finding.

The site's disappearance is more directly observable than the reason for it, but even that observation has limits. The original operation's storefront ceased functioning, according to consistent reporting. The technical cause, ownership decisions, payment-processor actions, and internal order status are not established by a public company statement or identified government record.

Still unknown

Several basic questions remain unanswered in public materials identified for this review:

Which agency or agencies took part in the reported warehouse action?
What legal authority, if any, supported the reported activity?
Were records, products, funds, or equipment collected?
Was any civil, administrative, or criminal proceeding opened under another name?
Who controlled the original operation when it went offline?
What became of each pending order or payment?
Does any current site using similar branding have a documented connection to the former operator?

An unknown is not evidence for either conclusion. It means the available public record does not support a definite statement. New primary documents could change that assessment, but later vendor articles repeating one another would not by themselves resolve it.

Researchers can apply the same distinction to product files. A certificate image is a claim until the issuing laboratory, tested sample, batch identifier, date, and reported methods can be connected. The lot-level certificate review guide explains the fields that make a report useful for verification.

The successor-site problem

Once a known storefront disappears, the name may continue circulating through old links, search results, social accounts, archived reviews, or newly registered storefronts. Industry trackers report that sites now trading under the Amino Asylum name are unverified successors or clones. That is attributed reporting, not a government determination about each site.

A familiar logo or product naming pattern cannot establish continuity. The same applies to a claim that a store has returned under new management. Operational continuity requires evidence linking the current seller to the prior business, and product reliability requires current batch documentation regardless of who owns the name.

Searching for an Amino Asylum alternative should therefore begin as a new-vendor review. Do not transfer assumptions from the old business to a new domain, a reseller, or a successor claim. Authenticate the current operator and its current inventory from scratch.

Useful identity checks include:

A consistent legal or operating name across invoices, policies, support messages, and payment records.
Current contact information that receives specific, verifiable replies.
Clear fulfillment terms and a stated US shipping origin when US fulfillment is claimed.
Stable product and lot identifiers that appear on both the item and its supporting report.
Laboratory reports that can be checked with the named laboratory rather than accepted as storefront images alone.
Policies that consistently frame products for laboratory research rather than personal outcomes.

These checks do not prove that two businesses are connected. They establish whether the current seller provides enough information to assess on its own terms.

A documentation-first verification checklist

Supplier verification works best as a repeatable process. The research supplier comparison framework gives the broader structure; the checklist below focuses on records a researcher can inspect before placing an order.

Match the report to the offered lot

The product page, item label, and certificate should share a lot or batch identifier. A generic report for the same compound does not establish what was measured in the lot currently offered. Confirm the analysis date, sample description, named laboratory, methods, and reported results. Curo's published quality and testing criteria show the kind of testing policy that can be compared with the underlying batch files.

Confirm the laboratory independently

Use the laboratory's own contact channel to verify that it issued the report when practical. Check whether the report identifier, client name, sample description, and date align. A polished PDF is not a substitute for provenance, and a QR code is useful only if its destination and record are authentic.

Preserve records outside the storefront

Save the product listing, lot certificate, invoice, fulfillment details, and relevant supplier communication with the project file. A storefront can change or disappear, while the research record still needs to show what material was received and what documentation accompanied it.

Review operations separately from analytical records

Batch analysis and business reliability answer different questions. A report describes a submitted sample. It does not establish inventory control, fulfillment performance, support availability, or the identity of a successor operator. Review payment terms, guest checkout availability, shipping origin, contact responsiveness, and refund language as separate operational evidence.

Check the research-use framing

Supplier pages, product descriptions, support materials, and promotions should use a consistent laboratory context. Curo's research-use-only standards state that boundary directly. No product document should be read as human-use guidance or as evidence of a medical outcome. The FDA has stated in warning letters that a research-use label does not control intended use when the rest of a site shows human-use promotion, which is why framing consistency belongs on any vendor checklist.

If you are replacing this vendor

Curo offers a curated catalog for research use, US fulfillment, guest checkout, and card, crypto, Zelle, and Cash App payment options. Every batch is third-party tested, and certificates are publicly readable without an account. Detailed compound documentation is also available through Insights and the help center.

Those features do not answer unresolved questions about the former vendor. They provide current records and operating terms that a researcher can evaluate directly. The same checklist should be applied to Curo and to any other source under consideration.

Frequently Asked Questions

What happened to Amino Asylum?

Industry reporting says a federal or FDA warehouse action occurred in June 2025, after which the original site went offline, pending orders remained unfulfilled, and no customer notice appeared. No public FDA or DOJ release, indictment, or charging document naming the vendor has been identified, so the action remains widely reported rather than established in an identified primary public record.

Is the Amino Asylum raid confirmed by a public government record?

Not in the records identified for this article. The reported warehouse action appears across industry coverage, but no public government release or court filing naming the company was found. The Paradigm Peptides DOJ case is documented and separate.

What should define an Amino Asylum alternative?

Use current evidence: an identifiable operator, lot-matched third-party reports, laboratory-verifiable report details, clear fulfillment and payment terms, responsive support, and consistent laboratory-research framing. A familiar name or similar catalog does not establish continuity.

Are current sites using the name connected to the original company?

That connection is unknown. Industry trackers describe current same-name sites as unverified successors or clones, but that remains attributed reporting. Each operator should provide its own identity, inventory, lot, laboratory, and fulfillment records for independent review.